122 related articles for article (PubMed ID: 36958125)
1. Contrast-enhanced CT parameters predict short-term tumor response in patients with hepatocellular carcinoma who received sequential combined anti-angiogenesis and immune checkpoint inhibitor treatment.
Feng Y; Zhang H; Ren Q; Li C; Liu S; Zheng C; Xia X
Eur J Radiol; 2023 May; 162():110784. PubMed ID: 36958125
[TBL] [Abstract][Full Text] [Related]
2. Early prediction of 1-year tumor response of hepatocellular carcinoma with lipiodol deposition pattern through post-embolization cone-beam computed tomography during conventional transarterial chemoembolization.
Tsai YC; Shih JH; Hwang HE; Chiu NC; Lee RC; Tseng HS; Liu CA
Eur Radiol; 2021 Oct; 31(10):7464-7475. PubMed ID: 33765160
[TBL] [Abstract][Full Text] [Related]
3. Quantitative Parameters of Contrast-Enhanced Ultrasound Predicting the Response to Combined Immune Checkpoint Inhibitor and Anti-angiogenesis Therapies for Unresectable Hepatocellular Carcinoma.
Zhang Y; Zheng R; Liu M; Zhang X; Sun Y; Shen H; Chen S; Cai H; Guo W; Xie X; Liu B; Huang G
Ultrasound Med Biol; 2024 Mar; 50(3):352-357. PubMed ID: 38072718
[TBL] [Abstract][Full Text] [Related]
4. Hepatic Tumor Stiffness Measured by Shear Wave Elastography Is Prognostic for HCC Progression Following Treatment With Anti-PD-1 Antibodies Plus Lenvatinib: A Retrospective Analysis of Two Independent Cohorts.
Yuan G; Xie F; Song Y; Li Q; Li R; Hu X; Zang M; Cheng X; Lu G; Huang J; Fan W; Rong X; Sun J; Chen J
Front Immunol; 2022; 13():868809. PubMed ID: 35757765
[TBL] [Abstract][Full Text] [Related]
5. Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST).
Jiang T; Kambadakone A; Kulkarni NM; Zhu AX; Sahani DV
Invest Radiol; 2012 Jan; 47(1):11-7. PubMed ID: 21512396
[TBL] [Abstract][Full Text] [Related]
6. Investigation of deep learning model for predicting immune checkpoint inhibitor treatment efficacy on contrast-enhanced computed tomography images of hepatocellular carcinoma.
Nakao Y; Nishihara T; Sasaki R; Fukushima M; Miuma S; Miyaaki H; Akazawa Y; Nakao K
Sci Rep; 2024 Mar; 14(1):6576. PubMed ID: 38503827
[TBL] [Abstract][Full Text] [Related]
7. Advanced Hepatocellular Carcinoma: Pretreatment Contrast-enhanced CT Texture Parameters as Predictive Biomarkers of Survival in Patients Treated with Sorafenib.
Mulé S; Thiefin G; Costentin C; Durot C; Rahmouni A; Luciani A; Hoeffel C
Radiology; 2018 Aug; 288(2):445-455. PubMed ID: 29584597
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Texture Analysis Parameter for Response Prediction in Patients with Hepatocellular Carcinoma Undergoing Drug-eluting Bead Transarterial Chemoembolization (DEB-TACE) Using Biphasic Contrast-enhanced CT Image Data: Correlation with Liver Perfusion CT.
Kloth C; Thaiss WM; Kärgel R; Grimmer R; Fritz J; Ioanoviciu SD; Ketelsen D; Nikolaou K; Horger M
Acad Radiol; 2017 Nov; 24(11):1352-1363. PubMed ID: 28652049
[TBL] [Abstract][Full Text] [Related]
9. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
[TBL] [Abstract][Full Text] [Related]
10. Preoperative normalized iodine concentration derived from spectral CT is correlated with early recurrence of hepatocellular carcinoma after curative resection.
Luo N; Li W; Xie J; Fu D; Liu L; Huang X; Su D; Jin G
Eur Radiol; 2021 Apr; 31(4):1872-1882. PubMed ID: 33037444
[TBL] [Abstract][Full Text] [Related]
11. Radiomics signature based on CECT for non-invasive prediction of response to anti-PD-1 therapy in patients with hepatocellular carcinoma.
Cui H; Zeng L; Li R; Li Q; Hong C; Zhu H; Chen L; Liu L; Zou X; Xiao L
Clin Radiol; 2023 Feb; 78(2):e37-e44. PubMed ID: 36257868
[TBL] [Abstract][Full Text] [Related]
12. Computed tomography findings of sorafenib-treated hepatic tumors in patients with advanced hepatocellular carcinoma.
Kim MJ; Choi JI; Lee JS; Park JW
J Gastroenterol Hepatol; 2011 Jul; 26(7):1201-6. PubMed ID: 21371120
[TBL] [Abstract][Full Text] [Related]
13. Development and Validation of a Contrast-Enhanced CT-Based Radiomics Nomogram for Prediction of Therapeutic Efficacy of Anti-PD-1 Antibodies in Advanced HCC Patients.
Yuan G; Song Y; Li Q; Hu X; Zang M; Dai W; Cheng X; Huang W; Yu W; Chen M; Guo Y; Zhang Q; Chen J
Front Immunol; 2020; 11():613946. PubMed ID: 33488622
[TBL] [Abstract][Full Text] [Related]
14. Irreversible electroporation of hepatocellular carcinoma: preliminary report on the diagnostic accuracy of magnetic resonance, computer tomography, and contrast-enhanced ultrasound in evaluation of the ablated area.
Granata V; de Lutio di Castelguidone E; Fusco R; Catalano O; Piccirillo M; Palaia R; Izzo F; Gallipoli AD; Petrillo A
Radiol Med; 2016 Feb; 121(2):122-31. PubMed ID: 26345332
[TBL] [Abstract][Full Text] [Related]
15. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
16. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
17. Utility of non-contrast-enhanced CT for improved detection of arterial phase hyperenhancement in hepatocellular carcinoma.
Hennedige T; Yang ZJ; Ong CK; Venkatesh SK
Abdom Imaging; 2014 Dec; 39(6):1247-54. PubMed ID: 24943135
[TBL] [Abstract][Full Text] [Related]
18. Multimodal Imaging Response after the Singular or Combination Treatments of Vascular Endothelial Growth Factor Inhibitor and Immune Checkpoint Inhibitor.
Ren Y; Pan F; Kan X; Wang J; Han P; Yan J; Li L; Sun P; Liu CY; Bao Q; Yang L; Zheng C
Mol Pharm; 2022 Oct; 19(10):3664-3672. PubMed ID: 35976154
[TBL] [Abstract][Full Text] [Related]
19. Hepatocellular carcinoma in cirrhotic liver disease: functional computed tomography with perfusion imaging in the assessment of tumor vascularization.
Ippolito D; Sironi S; Pozzi M; Antolini L; Ratti L; Alberzoni C; Leone EB; Meloni F; Valsecchi MG; Fazio F
Acad Radiol; 2008 Jul; 15(7):919-27. PubMed ID: 18572129
[TBL] [Abstract][Full Text] [Related]
20. Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors.
Xu S; Lai R; Zhao Q; Zhao P; Zhao R; Guo Z
Front Immunol; 2021; 12():794099. PubMed ID: 34950153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
